Publications
Detailed Information
Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ki Rim | - |
dc.contributor.author | Koh, Jiwon | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Kwon, Hyun Jung | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Paik, Jin Ho | - |
dc.date.accessioned | 2023-05-08T00:32:20Z | - |
dc.date.available | 2023-05-08T00:32:20Z | - |
dc.date.created | 2022-02-03 | - |
dc.date.created | 2022-02-03 | - |
dc.date.created | 2022-02-03 | - |
dc.date.created | 2022-02-03 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.citation | Journal of Pathology and Translational Medicine, Vol.56 No.1, pp.32-39 | - |
dc.identifier.issn | 2383-7837 | - |
dc.identifier.uri | https://hdl.handle.net/10371/191856 | - |
dc.description.abstract | Background: Primary adrenal (PA) diffuse large B cell lymphoma (DLBCL) was previously reported as an aggressive subset of DLBCL, but its genetic features were not sufficiently characterized. From our previous study of DLBCL with programmed death-ligand 1 (PD-L1) gene alterations, we focused on PD-L1 gene alterations in PA-DLBCL with clinicopathologic implications. Methods: We performed fluo-rescence in situ hybridization for PD-L1 gene translocation and amplification in PA-DLBCL (n = 18) and comparatively analyzed clinico-pathologic characteristics with systemic non-adrenal (NA)-DLBCL (n = 90). Results: PA-DLBCL harbored distinctive features (vs. NA-DLBCL), including high international prognostic index score (3-5) (72% [13/18] vs. 38% [34/90], p = .007), poor Eastern Cooperative Oncology Group performance score (>= 2) (47% [7/15] vs. 11% [10/90], p = .003), elevated serum lactate dehydrogenase (LDH) (78% [14/18] vs. 51% [44/87], p = .035) and MUM1 expression (87% [13/15] vs. 60% [54/90], p = .047). Moreover, PA-DLBCL showed frequent PD-L1 gene alterations (vs. NA-DLBCL) (39% [7/18] vs. 6% [5/86], p = .001), including translocation (22% [4/18] vs. 3% [3/87], p = .016) and amplification (17% [3/18] vs. 2% [2/87], p = .034). Within the PA-DLBCL group, PD-L1 gene-altered cases (vs. non-altered cases) tended to have B symptoms (p = .145) and elevated LDH (p = .119) but less frequent bulky disease (>= 10 cm) (p = .119). In the survival analysis, PA-DLBCL had a poor prognosis for overall survival (OS) and progression-free survival (PFS) (vs. NA-DLBCL; p = .014 and p = .004). Within the PA-DLBCL group, PD-L1 translocation was associated with shorter OS and PFS (p < .001 and p = .012). Conclusions: PA-DLBCL is a clinically aggressive and distinct subset of DLBCL with frequent PD-L1 gene alterations. PD-L1 gene translocation was associated with poor prognosis in PA-DLBCL. | - |
dc.language | 영어 | - |
dc.publisher | 대한병리학회 | - |
dc.title | Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.4132/jptm.2021.10.05 | - |
dc.citation.journaltitle | Journal of Pathology and Translational Medicine | - |
dc.identifier.wosid | 000721834200001 | - |
dc.identifier.scopusid | 2-s2.0-85124099862 | - |
dc.citation.endpage | 39 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 32 | - |
dc.citation.volume | 56 | - |
dc.identifier.kciid | ART002804340 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Paik, Jin Ho | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordAuthor | Malignant lymphoma | - |
dc.subject.keywordAuthor | Diffuse large B cell lymphoma | - |
dc.subject.keywordAuthor | Adrenal gland | - |
dc.subject.keywordAuthor | PD-L1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.